|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0023434,
umls-concept:C0030705,
umls-concept:C0059985,
umls-concept:C0087111,
umls-concept:C0393022,
umls-concept:C0544452,
umls-concept:C0677874,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1521991,
umls-concept:C1704632,
umls-concept:C1705294,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-2-2
|
|
pubmed:abstractText |
Modern combination strategies are active in chronic lymphocytic leukemia (CLL) but can have significant myelosuppression and immunosuppression that may require dose attenuation for safety. We explored a sequential treatment strategy to allow safe delivery of active agents at full doses. Previously, we studied sequential therapy with fludarabine followed by cyclophosphamide (F-->C). In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-10995003,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-11114313,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-11136261,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-11230486,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-11264154,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-11588025,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-12393429,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-15138165,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-15767648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-16179374,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-16219797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-16520464,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-17283364,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-17658394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-19075263,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-3931957,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-7680398,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-8057664,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-8400226,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-8652811,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19075280-8676625
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine,
http://linkedlifedata.com/resource/pubmed/chemical/fludarabine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BrentjensRenier JRJ,
pubmed-author:GencarelliAlison NAN,
pubmed-author:GoldeDavid WDW,
pubmed-author:HeaneyMark LML,
pubmed-author:JurcicJoseph GJG,
pubmed-author:LamannaNicoleN,
pubmed-author:MaslakPeterP,
pubmed-author:NoyArielaA,
pubmed-author:PanageasKatherine SKS,
pubmed-author:ScheinbergDavid ADA,
pubmed-author:WeissMark AMA,
pubmed-author:ZelenetzAndrew DAD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
491-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19075280-Adult,
pubmed-meshheading:19075280-Aged,
pubmed-meshheading:19075280-Antibodies, Monoclonal,
pubmed-meshheading:19075280-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:19075280-Antineoplastic Agents,
pubmed-meshheading:19075280-Antineoplastic Agents, Alkylating,
pubmed-meshheading:19075280-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19075280-Cyclophosphamide,
pubmed-meshheading:19075280-Drug Administration Schedule,
pubmed-meshheading:19075280-Female,
pubmed-meshheading:19075280-Flow Cytometry,
pubmed-meshheading:19075280-Follow-Up Studies,
pubmed-meshheading:19075280-Humans,
pubmed-meshheading:19075280-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:19075280-Male,
pubmed-meshheading:19075280-Middle Aged,
pubmed-meshheading:19075280-Polymerase Chain Reaction,
pubmed-meshheading:19075280-Remission Induction,
pubmed-meshheading:19075280-Vidarabine
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
|
|
pubmed:affiliation |
Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
